Studies have shown that recombinant ADAMTS-13 (rh ADAMTS-13) can be used for the treatment of patients with thrombotic thrombocytopenic purpura, reducing AKI in patients [7,8]. Here, ADAMTS13 is linked to acute kidney injury.